Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Fresenius Medical Care AG's Net Cash per Share or its related term are showing as below:
XSWX:FME's Price-to-Net-Cash is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 8.01 * Ranked among companies with meaningful Price-to-Net-Cash only.
Fresenius Medical Care AG (XSWX:FME) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Fresenius Medical Care AG Net Cash per Share Related Terms
Fresenius Medical Care AG Net Cash per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fresenius Medical Care AG Net Cash per Share Chart
XSWX:FME vs HCA, THC, DVA: Net Cash per Share Comparison
For the Medical Care Facilities subindustry, Fresenius Medical Care AG's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fresenius Medical Care AG Price-to-Net-Cash vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Fresenius Medical Care AG's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Fresenius Medical Care AG's Price-to-Net-Cash falls into.
Fresenius Medical Care AG Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Fresenius Medical Care AG's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fresenius Medical Care AG (XSWX:FME) has a Net Cash per Share of CHF-55.95 as of Mar. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Fresenius Medical Care AG and its competitors. According to the industry distribution chart, Fresenius Medical Care AG ranks #999999 out of 147 companies in the Healthcare Providers & Services industry.
Is Fresenius Medical Care AG's Net Cash per Share too high?
Fresenius Medical Care AG's current Net Cash per Share is CHF-55.95. Based on the distribution chart, Fresenius Medical Care AG ranks #999999 out of 147 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Fresenius Medical Care AG has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Fresenius Medical Care AG's Net Cash per Share compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Fresenius Medical Care AG ranks #999999 out of 147 companies for Net Cash per Share. This places Fresenius Medical Care AG in the lower half of its industry. The industry median Net Cash per Share is 8.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Healthcare Providers & Services company?
The median Net Cash per Share among Healthcare Providers & Services companies is 8.01, based on 147 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Fresenius Medical Care AG and its competitors. For the Healthcare Providers & Services industry, the median Net Cash per Share is 8.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fresenius Medical Care AG's current Net Cash per Share is CHF-55.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fresenius Medical Care AG stock overvalued right now?
Fresenius Medical Care AG (XSWX:FME) has a current Net Cash per Share of CHF-55.95. The stock's GF Value™ is CHF37.64, compared to a current price of CHF39.25 — trading 4.3% above its estimated fair value. The current Net Cash per Share is CHF-55.95. Fresenius Medical Care AG's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Fresenius Medical Care AG (XSWX:FME), the current Net Cash per Share is CHF-55.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fresenius Medical Care AG (XSWX:FME) Overvalued in 2026?
Based on GuruFocus' analysis, Fresenius Medical Care AG stock appears to be overvalued.
The current stock price of CHF39.25 is trading 4.3% above its estimated GF Value™ of CHF37.64.
Key valuation signals for XSWX:FME:
Net Cash per Share: CHF-55.95
GF Value™: CHF37.64 vs. price of CHF39.25 (4.3% above fair value)
No single metric tells the full story. See the XSWX:FME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.
75GF Score
Get the complete analysis for XSWX:FME
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:FME has been successfully added to your 
